Literature DB >> 11679157

Delayed emergence of bovine leukemia virus after vaccination with a protective cytotoxic T cell-based vaccine.

L Mateo1, J Gardner, A Suhrbier.   

Abstract

In a previous study eight MHC class I-matched sheep were vaccinated with a minimal cytotoxic T lymphocyte (CTL) peptide epitope vaccine and were challenged with the retrovirus, bovine leukemia virus (BLV). Half the vaccinated animals remained PCR negative after challenge, whereas the remaining half and the placebo group became PCR positive within 4 weeks postchallenge (Hislop AD, Good MF, Mateo L, Gardner J, Gatei MH, Daniel RCW, Meyers BV, Lavin MF, and Suhrbier A: Nat Med 1998;4:1193). Here we show that neither epitope mutations nor processing differences explained why half the peptide-vaccinated animals failed to resist the BLV challenge. However, in these animals the development of BLV-induced lymphosarcomas was significantly delayed compared with the placebo group, suggesting a role for CTLs in preventing retrovirus-induced cancers. Importantly, two of the initially protected animals become PCR positive after approximately 1.5 years, indicating extended suppression but not elimination of challenge virus by vaccine-induced CTLs. The late emergence of virus could not be explained by epitope escape mutations or the loss of memory CTL responses. We speculate that high levels of effector CTL may be needed to protect animals from a postchallenge viremia and maintenance of such effector CTLs, rather than memory CTLs, may be required to prevent subsequent emergence of virus from latent pools.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679157     DOI: 10.1089/088922201753197114

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.

Authors:  Itaru Anraku; Tracey J Harvey; Richard Linedale; Joy Gardner; David Harrich; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Kunjin virus replicon vectors for human immunodeficiency virus vaccine development.

Authors:  Tracey J Harvey; Itaru Anraku; Richard Linedale; David Harrich; Jason Mackenzie; Andreas Suhrbier; Alexander A Khromykh
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 3.  Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.

Authors:  Sabrina M Rodríguez; Arnaud Florins; Nicolas Gillet; Alix de Brogniez; María Teresa Sánchez-Alcaraz; Mathieu Boxus; Fanny Boulanger; Gerónimo Gutiérrez; Karina Trono; Irene Alvarez; Lucas Vagnoni; Luc Willems
Journal:  Viruses       Date:  2011-07-19       Impact factor: 5.048

Review 4.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

5.  Early and transient reverse transcription during primary deltaretroviral infection of sheep.

Authors:  Carole Pomier; Maria T Sanchez Alcaraz; Christophe Debacq; Agnes Lançon; Pierre Kerkhofs; Lucas Willems; Eric Wattel; Franck Mortreux
Journal:  Retrovirology       Date:  2008-02-01       Impact factor: 4.602

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.